What Does The Future Of Psychedelics as Therapy Look Like?
Last reviewed and updated: June 1, 2026.
Key Takeaways
| Legal now (U.S.) | Ketamine (nationwide); psilocybin facilitated sessions in Oregon and Colorado; MDMA in clinical trials only |
| Biggest 2020–2025 development | Oregon and Colorado launched legal psilocybin programs; Australia approved psilocybin as medicine; MDMA Phase 3 trials completed |
| MDMA status | FDA declined approval in 2024 on data quality grounds; appeal ongoing; 67% PTSD remission rate in Phase 3 |
| Biggest remaining barrier | Cost and insurance — most psychedelic therapies require full out-of-pocket payment |
| What’s coming | Ibogaine (opioid/TBI trials underway), DMT protocols, better insurance coverage frameworks |
Psychedelics have sparked a lot of intrigue in recent years, especially with supportive research and news of legalizing supervised use. Still, the future of psychedelics remains a question — and one that’s hard to predict.
With alternative medicine gaining popularity, what comes next for these types of drugs? Here’s what we know thus far.
RELATED: The 10 Best Psychedelic Documentaries
Future of Psychedelics: The University Approach
Universities around the world are beginning to fund dedicated psychedelic research facilities. For instance, two are the Centre for Psychedelic Research at the Imperial College in London, and the Center for Psychedelic and Consciousness Research at John Hopkins University.
Psychedelics shows promise in having a major impact on neuroscience and psychiatry in the coming years. For that reason, universities are beginning to study the effects more closely.
With universities offering funding, support, and resources, expect a higher number of trials and new studies. Over the next decade, more widespread use of psychedelics is more of a reality than just a possibility.
Since their foundation, both centers have helped lead studies on the effects of psychedelics related to depression, eating disorders, alcohol abuse, and Alzheimer’s disease. It’s even an interesting option for treating asthma.
Many of the studies so far have shown great promise. However, studies often limit participants, so size and reach remains an issue with results.
One of the biggest moments in the industry was when the FDA designated ketamine as a “breakthrough therapy”. Due to that ruling, there are now over 1800 ketamine therapy clinics in the United States. Here’s how to find the best ketamine therapy clinic near you.
RELATED: How Morgan Stanley’s Research Impacts The Future Of Psychedelic Investment
Worldwide Organizations and Associations
Since the early psychedelic research started showing great potential in treating some serious mental disorders, many non-profit and educational organizations and associations have formed worldwide. Some of the most important organizations include:
Hakomi Institute. The Hakomi Institute is built on the original body-inclusive psychotherapy method developed by its founder, Ron Kurtz. Their mission includes training and helping counselors, psychotherapists, and social workers worldwide enrich the treatments to offer more to patients.
Canadian Psychedelic Association (CPA). CPA dedicates itself to increasing public understanding and access to safe and effective psychedelic treatments. Through educational experientials and safe practices, CPA helps people understand the potential of these alternative methods.
Without these organizations, patients would be on their own to explore and discover what psychedelics are all about. With much conflicting and confusing information, advancing to a higher number of volunteers for studies and trials could also prove difficult.
RELATED: What Are Psychedelics? We Explain The Differences From Other Drugs
The Greatest Challenges For the Future of Psychedelics
Some of the greatest obstacles and challenges to expanding psychedelic therapy access include:
Money
About 99 percent of human psychopharmacology research still comes from the Big Pharma industry. On the contrary, most psychedelic research comes from charitable donations or philanthropy. But with investors beginning to involve themselves into the psychedelics industry, things could be changing. Breaking those financial barriers are holding psychedelic research back.
Insurance Coverage and Accessibility
Most insurance companies still resist payment for psychotherapy. To make changes, it’s crucial to educate insurance providers and health policy regulators of the importance of psychedelic-assisted therapy.
RELATED: Magic Mushrooms Offer Hope As A Potential Future Treatment for Anorexia Nervosa
Certifications
When psychedelic treatment becomes legal, getting it to the patients in need will be the key challenge. Likewise, educating and certifying psychotherapists to administer these drugs will be crucial. That’s where the aforementioned non-profit organizations will play a huge part, ensuring adequate training in therapeutic principles, ethics, and other vital aspects of delivering psychedelic-assisted psychotherapy.
RELATED: Federal Health Agency Recognizes Psilocybin’s Therapeutic Potential For First Time
Access to Information
Lastly, it’s going to be important to spread awareness around psychedelic-assisted psychotherapy. Removing the stigma around these compounds that define them as harmful drugs is critical. The public must build trust in the process and understand the safety. Luckily there is more info out there than ever before. Trusted, mainstream publications are writing about psychedelic therapies every day, it seems. And the more information that is published, the faster the stigmas fall. And the beauty of this industry is that it is backed by science.
The trajectory of psychedelic medicine has shifted from “promising early research” to “active clinical programs, legal services, and real patients being treated.” The challenges of funding, insurance coverage, and certification remain — but they are being actively addressed by the organizations, researchers, and policymakers already in the field. See the section below for what has actually unfolded since this article was first published in 2020.
RELATED READING
- Psychedelics Show Promise For A Range Of Mental Health Concerns
- What Is Ketamine Therapy? Here’s What The Research Says
- Find a Verified Ketamine Clinic Near You
Where We Are Now: What Has Actually Happened Since 2021
This article was originally written in late 2020, when psilocybin therapy was still entirely in the research phase and “the future of psychedelics” was genuinely uncertain. The five years since have moved faster than most in the field anticipated. Here is what has happened.
Psilocybin Is Now Legal in Two U.S. States
Oregon launched the first legal psilocybin service centers in the United States in 2023 under Measure 109, passed by voters in 2020. Licensed facilitators can now administer psilocybin sessions to adults without a psychiatric diagnosis requirement. Colorado followed with Proposition 122, with licensed facilitator programs beginning in 2025. Several U.S. cities — Denver, Oakland, Santa Cruz, Seattle, Ann Arbor, Detroit, and Washington D.C. among them — have decriminalized possession. International access has expanded too: Australia’s Therapeutic Goods Administration (TGA) approved psilocybin for treatment-resistant depression in 2023, making Australia the first country to formally approve it as a medicine.
MDMA Hit a Regulatory Wall — But Isn’t Done
MAPS (Multidisciplinary Association for Psychedelic Studies) completed Phase 3 clinical trials for MDMA-assisted therapy for PTSD — results showing 67% of participants no longer met PTSD diagnostic criteria, versus 32% for placebo. The FDA declined initial approval in August 2024, citing concerns about data quality and trial blinding methodology from the sponsor (Lykos Therapeutics). The appeal process continues and new trials are underway. MDMA-assisted therapy remains available only through clinical trials in the U.S., but most researchers still consider it one of the most promising PTSD treatments in development.
Ketamine Has Gone Mainstream
The article noted the FDA’s ketamine Breakthrough Therapy designation and 1,800 clinics — that is now the floor, not the ceiling. Ketamine therapy is now widely regarded as a mainstream (if still often out-of-pocket) psychiatric treatment, with FDA-approved esketamine (Spravato) specifically designated for treatment-resistant depression and major depressive disorder with suicidal ideation. The growth in availability has also driven scrutiny: regulatory bodies are increasingly focused on quality-of-care standards as the market has expanded rapidly.
What’s Still Ahead
The next wave of psychedelic medicine research is focused on ibogaine (for opioid use disorder and TBI — the first FDA Phase 2 trials are now underway), DMT and 5-MeO-DMT (for depression; short duration makes it practical as a clinical session), and ketamine combinations (ketamine + psychotherapy protocols with measurable long-term outcomes). Insurance coverage remains the biggest access barrier — most psychedelic therapies require full out-of-pocket payment. And therapist training and certification infrastructure is still being built: programs at CIIS, Naropa, and MAPS have certified thousands of therapists, but the training pipeline remains a constraint on how many patients can actually be served.
Frequently Asked Questions
Is psychedelic therapy legal in the United States?
It depends on the substance and the state. Ketamine therapy is legal nationwide — it’s a Schedule III substance that can be prescribed by any physician, and over 1,800 verified clinics offer it. Psilocybin facilitated sessions are legal in Oregon (since 2023) and Colorado (since 2025). MDMA, LSD, and most other classical psychedelics remain Schedule I federally and are only available through FDA-approved clinical trials. Possession of psilocybin has been decriminalized (not legalized) in several U.S. cities.
Why did the FDA reject MDMA therapy?
In August 2024, the FDA declined to approve MDMA-assisted therapy for PTSD developed by Lykos Therapeutics (formerly MAPS PBC). The agency cited concerns about the integrity of trial data, the ability to maintain blinding in the trials, and questions about the generalizability of results. The efficacy data itself was strong — 67% of MDMA therapy participants no longer met PTSD diagnostic criteria, versus 32% for placebo. The sponsor has appealed and new trials are underway to address the FDA’s specific concerns. Most researchers believe MDMA-assisted therapy will eventually receive approval, though the timeline has been pushed back significantly.
What is the biggest barrier to psychedelic therapy access right now?
Cost and insurance coverage are the primary barriers. Ketamine therapy typically runs $300–$500 per session with no insurance coverage for the majority of patients. Oregon psilocybin sessions cost $800–$2,000 depending on the facilitator. MDMA and psilocybin in clinical trials are provided free to participants. Beyond cost, the second major barrier is trained provider availability — the number of certified psychedelic therapists is still a fraction of what will be needed if these treatments become broadly approved and mainstream.
Which psychedelic therapy has the most evidence right now?
Ketamine has the most established evidence base and the widest legal availability. For classical psychedelics, psilocybin has the strongest Phase 2 and 2b data — for treatment-resistant depression, end-of-life anxiety, and alcohol use disorder. MDMA has the most advanced PTSD-specific data (Phase 3 complete, despite the FDA rejection). The Johns Hopkins Center for Psychedelic and Consciousness Research and Imperial College London’s Centre for Psychedelic Research remain the world’s most prolific academic producers of clinical evidence.
